Boston Scientific announced a €75 million (approximately $88 million) investment in its Galway site, including the expansion of its research and development (R&D) capabilities.
The development, which is supported by funding from the Irish government through IDA Ireland, includes laboratories to enhance the ability of teams in Galway to design, develop and test next-generation medical technologies across a range of cardiovascular therapies.
The expanded capability will support priority programs across structural heart, cardiovascular and endoscopy, as well as emerging areas such as heart failure and renal denervation technologies.
“We are seeing strong momentum across our cardiovascular business, and this investment reflects the important role the Galway site plays in that progress,” said Lance Bates, executive vice president and president, Interventional Cardiology and Vascular Therapies at Boston Scientific. “The local team is delivering complex, highly collaborative work that is advancing meaningful innovation for patients. The strength of the site, the talent in Ireland and the support of the Irish Government and IDA Ireland give us confidence to continue investing in our future growth.”
Boston Scientific has a presence in Ireland spanning more than 30 years, with more than 7,000 employees across sites in Galway, Cork and Clonmel producing more than 30 million devices each year for patients worldwide.
Medical devices exported from the Galway facility every year include drug-coated devices, vascular balloons and heart and oesophageal stents. These products help treat patients with conditions including heart disease, vascular disease, oesophageal cancer and those at risk of stroke.
